



Silvia Pomella

📍 Department of Clinical Sciences and Translational Medicine,
University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy

✉ silvia.pomella@uniroma2.it

WORKING EXPERIENCES

- (01/2025 – Today) RTT at University Tor Vergata, Rome, Italy
- (02/2022 – Today) Oncology Affiliated researcher at Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- (02/2022 – 01/2025) RTD-A at University Tor Vergata, Rome, Italy
- (01/2018 – Today) Oncology Post-Doc at Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- (03/2018 – 04/2019) Oncology Post-Doc at National Institute of Health (NIH), Bethesda, USA
- (02/2015 – 12/2017) Oncology PhD student in Cellular and Molecular Biology, at Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
Department of Oncohematology, (Head Prof. Franco Locatelli). Epigenetics of Pediatric Sarcoma's Laboratory (PI Dr. Rossella Rota).
- (01/2014 – 12/2014) Post Lauream Researcher at Istituto Dermopatico dell'Immacolata (IDI) Rome, Italy
Department of Vascular Pathology (Head Dr. Maurizio Colognesi Capogrossi) Epigenetics Laboratory (PI Dr. Roberta Ciarapica).
- (11/2012 – 01/2014) Scientific and Data Manager Collaborator at Policlinico A. Gemelli, Rome, Italy
Natural Regulation of Fertility (Head Prof. Elena Giacchi)

EDUCATION AND TRAINING

- (10/2014 – 12/2017) Research Doctorate School in Cellular and Molecular Biology
University Tor Vergata, Rome, Italy
- (2014) Qualification as Professional Biologist
University Tor Vergata, Rome, Italy
- (10/2009 – 10/2011) Master's Degree in Industrial and Molecular Biotechnology
University Alma Mater Studiorum, Bologna, Italy
Graduated with honours (110/110 cum laude)
- (10/2006 – 07/2009) Bachelor's Degree in Sanitary Biotechnology
University Cattolica del Sacro Cuore, Rome, Italy
Graduated with honours (110/110 cum laude)

ORAL AND POSTER PRESENTATIONS

- Poster at AACR, San Diego, CA, USA. April **2024**.
Poster Title: Targeting resistance to BET inhibitors in FP- RMS. Cassandri M, Ferraro E, D'Archivio L, Aiello FA, Chou, HC, Song Y, Gryder BE, Wei JS, Sidoli S, Hawley RG, Rota R, Locatelli F, Khan J, **Pomella S**.
- Poster at AACR, San Diego, CA, USA. April **2024**.
Poster Title: HDAC3 sustains resistance to hypofractionated radiotherapy in fusion positive rhabdomyosarcoma cells. Cassandri M, Porrazzo A, **Pomella S**, Camero S, Aiello FA, D'Archivio L, Zwergel C, Noce B, Tomaciello M, Vulcano F, Milazzo L, Pedini F, Signore M, Fanzani A, Marchese C, Minniti G, Valente S, Mai A, Megiorni F, Rota R, Marampon F.
- Invited Speaker at Summer's Way Rhabdomyosarcoma workshop, Denver, CO, USA. October **2023**.
Presentation Title: Targeting resistance to BET inhibitors in FP- RMS.
- Invited Speaker at Cell Death and Disease, Como, Italy. September **2023**.
Presentation Title: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo.
- Poster at ACC, Rome, Italy. September **2022**.
Poster Title: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo. Cassandri M, **Pomella S**, Perrone C, Pezzella M, Wachtel M, Cardinale A, Cossetti C, Colletti M, Di Giannatale A, Carlesso N, Shipley J, Miele L, Schafer B, Velardi E, Houghton P, Gryder B, Milano GM, Alaggio R, Quintarelli C, De Angelis B, Locatelli F, Rota R.
- Oral presentation at AACR, New Orleans, LO, USA. April **2022**.
Presentation Title: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and

- is counteracted by neddylation inhibition in vitro and in vivo.
7. Invited Speaker at Epigenetic Seminar Series, Montreal, QC, Canada. February **2022**.
Presentation Title: Enhancer dampening by transcription factor SNAI2 blocks myogenesis in rhabdomyosarcoma.
 8. Poster at ACC, Rome, Italy. September **2021**.
Poster Title: SMOX induction sensitizes Fusion-Negative Rhabdomyosarcoma cells to radiation. Perrone C, **Pomella S**, Cassandri M, Giuliani S, Quintarelli, Locatelli F, De Angelis B, Mariottini P, Marampon F, Cervelli M, Rota R.
 9. Poster at AACR, Philadelphia, PA, USA. April **2020**.
Poster Title: Identification of novel inhibitors of the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma. Kim YY, Hawley R, Gryder BE, **Pomella S**, Kowalczyk J, Sinniah R, Song Y, Khan J.
 10. Poster at ACC, Rome, Italy. November **2019**.
Poster Title: NOTCH inhibition leads to MET activation in Rhabdomyosarcoma cells. Perrone C, Pezzella M, Pericoli G, Camera A, Cembrola B, **Pomella S**, Cassandri M, Cossetti C, Vinci M, de Billy E, Quintarelli C, Locatelli F, De Angelis B, Rota R.
 11. Poster at AACR, Montreal, QC, Canada. September **2019**.
Poster Title: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy. Cheuk A, Shivaprasad N, Schneider D, Yohe ME, Tan M, Azorsa P, Sams R, **Pomella S**, Gryder BE, Rota R, Stanton B, Wei J, Song YM, Wen X, Sindiri S, Kumar J, Hawley RG, Chung YG, Zhelev DV, Zhu Z, Dimitrov DS, Hewitt SM, Dropulic B, Orentas RJ, Khan J.
 12. Poster at AACR, Montreal, QC, Canada. September **2019**.
Poster Title: Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma. **Pomella S**, Sreenivas P, Gryder BE, Wang L, Cassandri M, Baxi K, Hensch NR, Carcarino E, Song Y, Yohe M, Amadio B, Caruana I, De Stefanis C, De Vito R, Locatelli F, Chen Y, Chen EY, Houghton P, Khan J, Rota R, Ignatius MS.
 13. Poster at AACR, Atlanta, GA, USA. March **2019**.
Poster Title: SNAI2 blocks differentiation and promotes tumor growth by selective inhibition of the MYOD1 differentiation program in Embryonal Rhabdomyosarcoma. **Pomella S**, Sreenivas P, Gryder BE, Wang L, Cassandri M, Baxi K, Hensch N, Song Y, Yohe ME, Chen E, Houghton P, Khan J, Rota R, Ignatius M.
 14. Poster at AACR, Chicago, IL, USA. April **2018**.
Poster Title: SNAI2 inhibition promotes myogenic differentiation and prevents tumorigenic features of embryonal Rhabdomyosarcoma cells. **Pomella S**, Pietrobono S, Carcarino E, Cossetti C, Locatelli F, Rota R.
 15. Poster at EACR-AACR-SIC Special Conference, Florence, Italy. June **2017**.
Poster Title: Reduction of SKP2 prevents cell cycle progression and induces differentiation in embryonal rhabdomyosarcoma by increasing p21Cip1 and MYOG levels. **Pomella S**, Cossetti C, Carcarino E, Gualtieri A, Raimondi L, Walters Z, Shipley J, Miele L, Locatelli F, Rota R.
 16. Poster at AACR, Washington DC, DC, USA. April **2017**.
Poster Title: Targeting the crosstalk between MET and Notch signaling in Rhabdomyosarcoma. Rota R, Cossetti C, **Pomella S**, Gualtieri A, Carcarino E, Ponzetto C, Taulli R, Miele L, Locatelli F.
 17. Poster at AACR New Orleans, LO, USA. April **2016**.
Poster Title: miR-301 expression is deregulated in rhabdomyosarcoma. Rota R, Gualtieri A, Cossetti C, **Pomella S**, Adesso L, Locatelli F.
 18. Poster at AHA, New Orleans, LO, USA. November **2016**.
Poster Title: Modulation of H3K27me3 epigenetic mark affects E-cadherin expression and improves diabetic wound healing. **Pomella S**, D'Aria S, Beji S, Antonini A, Dell'Ambra E, Mai A, Magenta A, Mensà E, Platone A, Mascellari L, Bartolotta V, Antonicelli R, Furguele S, Capogrossi MC, Ciarapica R.
 19. Poster at ASH, San Diego, CA, USA. December **2011**.
Poster Title: The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL). Iacobucci I, Cattina F, **Pomella S**, Lonetti A, Derenzini E, Brighenti E, Ferrari A, Papayannidis C, Verga Falzacappa M V, Guadagnuolo V, Aluigi M, Ottaviani E, Formica S, Abbenante M C, Soverini S, Russo D, Pane F, Pellicci P G, Baccarani M, Martinelli G.
 20. Poster at ASH, San Diego, CA, USA. December **2011**.
Poster Title: ARF Loss, a Negative Prognostic Factor in Ph+ Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. Iacobucci I, Cattina F, **Pomella S**, Lonetti A, Ferrari A, Papayannidis C, Trino S, Erriquez D, Guadagnuolo V, Ottaviani E, Formica S, Soverini S, Paoloni F, Vignetti M, Russo D, Perini G, Baccarani M, Martinelli G.

AWARDS

1. Qualification for second class professor: From 17/12/2023 to 17/12/2034 SSD 06/N1 - Scienze Delle Professioni Sanitarie E Delle Tecnologie Mediche Applicate (ASN session 2021/2023)
2. Fondazione Umberto Veronesi Award **2022**
3. "Contributi premiali per i ricercatori e assegnisti di ricerca per rafforzare la condizione professionale e potenziare il sistema della ricerca del Lazio - Obiettivo di Policy 4 "Un'Europa più sociale" **2022**
4. Fondazione Umberto Veronesi Postdoctoral fellowship **2022**
5. Fondazione Umberto Veronesi Postdoctoral fellowship **2020**

6. Fondazione Umberto Veronesi Postdoctoral fellowship **2019**
7. Fondazione Umberto Veronesi Postdoctoral fellowship **2018**

GRANTS

1. Principal Investigator Ricerca Corrente 2024
2. Principal Investigator Ricerca Finalizzata Giovani Ricercatori 2021

REVIEWER ACTIVITY

Molecular Cancer, International Journal of Molecular Sciences, Cancers, Molecular Medicine, Molecular Oncology, Molecular and Cellular Pathology for Frontiers in Cell and Developmental Biology, Molecular Metabolism